Top

Published in:

01-07-2007 | Review Article

Imaging Non-Dopaminergic Function in Parkinson’s Disease

Author: David J. Brooks

Published in: Molecular Imaging and Biology | Issue 4/2007

Abstract

In Parkinson’s disease (PD), there is degeneration of the cholinergic, noradrenergic, and serotonergic systems in addition to dopaminergic projections. Function of these non-dopaminergic systems can be imaged with positron emission tomography (PET) and single photon emission computed tomography (SPECT) and correlated with motor and nonmotor symptomatology. In addition, neuronal loss in PD is associated with microglial activation. The role of microglia in driving the disease process remains uncertain. This review presents and discusses current findings in these areas.

Jellinger K (1987) The pathology of parkinsonism. In: Marsden CD, Fahn S (eds) Movement disorders 2. London: Butterworths, pp 124–165

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) The accuracy of the clinical diagnosis of Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMed

Litvan I, Macintyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, Mckee A, Brandel JP, Chaudhuri KR, Lai EC, D’olhaberriague L, Pearce RKB, Agid Y (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies. Arch Neurol 55:969–978, JulPubMedCrossRef

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRef

McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291PubMed

Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol (Berl) 106:518–526CrossRef

Lamarre Y (1984) Animal models of tremor. In: Findley LJ, Capildeo R (eds) Movement disorders: tremor. London: MacMillan Press, pp 183–194

Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2003) Tremor in Parkinson’s disease and serotonergic dysfunction: an (11)C-WAY 100635 PET study. Neurology 60:601–605PubMed

Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2000) Brain serotonin HT1A receptors in Parkinson’s disease with and without depression measured by positron emission tomography and 11C-WAY100635. In: Movement disorders. vol 15 Supp 3. 213

10.

Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN, Jr, Robinson RG (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 28:57–64PubMedCrossRef

11.

Kim SE, Choi JY, Choe YS, Choi Y, Lee WY (2003) Serotonin transporters in the midbrain of Parkinson’s disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 44:870–876PubMed

12.

Becker G, Berg D, Lesch KP, Becker T (2001) Basal limbic system alteration in major depression: a hypothesis supported by transcranial sonography and MRI findings. Int J Neuropsychopharmacol 4:21–31PubMedCrossRef

13.

Berg D, Supprian T, Hofmann E, Zeiler B, Jager A, Lange KW, Reiners K, Becker T, Becker G (1999) Depression in Parkinson’s disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol 246:1186–1193PubMedCrossRef

14.

Ding YS, Lin KS, Logan J, Benveniste H, Carter P (2005) Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. J Neurochem 94:337–351PubMedCrossRef

15.

Ding YS, Lin KS, Garza V, Carter P, Alexoff D, Logan J, Shea C, Xu Y, King P (2003) Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 50:345–352PubMedCrossRef

16.

Remy P, Doder M, Lees AJ, Turjanski N, Brooks DJ (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314–1322PubMedCrossRef

17.

Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 40:399–410PubMedCrossRef

18.

Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T (1998) Brain muscarinic receptors in progressive supranuclear palsy and Parkinson’s disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 65:155–163PubMedCrossRef

19.

Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745–1748PubMedCrossRef

20.

Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis CA, Davis JG, Moore RY, Dekosky ST (2005) Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 253:242–247PubMedCrossRef

21.

Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168–175PubMedCrossRef

22.

Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [(11)C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412PubMedCrossRef

23.

Jolkkonen J, Jenner P, Marsden CD (1995) l-dopa reverses altered gene expression of substance P but not enkephalin in the caudate–putamen of common marmosets treated with MPTP. Mol Brain Res 32:297–307PubMedCrossRef

24.

Jones AK, Watabe H, Cunningham VJ, Jones T (2004) Cerebral decreases in opioid receptor binding in patients with central neuropathic pain measured by [11C]diprenorphine binding and PET. Eur J Pain 8:479–485PubMedCrossRef

25.

Piccini P, Weeks RA, Brooks DJ (1997) Opioid receptor binding in Parkinson’s patients with and without levodopa-induced dyskinesias. Ann Neurol 42:720–726PubMedCrossRef

26.

Whone AL, Rabiner EA, Arahata Y, Luthra SK, Hargreaves R, Brooks DJ (2002) Reduced substance P binding in Parkinson’s disease complicated by dyskinesias: an F-18-L829165 PET study. Neurology 58:A488–A489

27.

Yoshita M (2000) Cardiac uptake of [123I]MIBG separates PD from multiple system atrophy. Neurology 54:1877–1878PubMed

28.

Druschky A, Hilz MJ, Platsch G, Radespiel-Troger M, Druschky K, Kuwert T, Neundorfer B (2000) Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 175:3–12PubMedCrossRef

29.

Reinhardt MJ, Jungling FD, Krause TM, Braune S (2000) Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 27:595–600PubMedCrossRef

30.

Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, Rascol O, Senard JM (2003) Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 18:890–897PubMedCrossRef

31.

Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, Takashima H, Tsujihata M (1999) Loss of 123I-MIBG uptake by the heart in Parkinson’s disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 40:371–375PubMed

32.

Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH (1999) Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 53:1020–1025PubMed

33.

Yoshita M (1998) Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60–67PubMedCrossRef

34.

Hirayama M, Hakusui S, Koike Y, Ito K, Kato T, Ikeda M, Hasegawa Y, Takahashi A (1995) A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 53:230–234PubMedCrossRef

35.

Berding G, Schrader CH, Peschel T, van den Hoff J, Kolbe H, Meyer GJ, Dengler R, Knapp WH (2003) [N-methyl 11C]meta-Hydroxyephedrine positron emission tomography in Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 30:127–131PubMedCrossRef

Title: Imaging Non-Dopaminergic Function in Parkinson’s Disease
Author: David J. Brooks
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 4/2007
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-007-0084-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Imaging Non-Dopaminergic Function in Parkinson’s Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2007

Neurodegenerative Disease

Understanding the Placebo Effect: Contributions from Neuroimaging

The Application of Positron-Emitting Molecular Imaging Tracers in Alzheimer’s Disease

MR Spectroscopy in Neurodegenerative Disease

Functional and Anatomical Magnetic Resonance Imaging in Parkinson’s Disease

In Vitro Imaging Techniques in Neurodegenerative Diseases